Best Peptides for Weight Loss in 2026
The most effective weight loss peptides in 2026 are tirzepatide (up to 22.5%), retatrutide (up to 24.2%, investigational), and semaglutide (14.9-15.8%); this ranking compares efficacy, FDA status, and safety across the leading candidates.
Overview
The weight-loss peptide landscape has evolved rapidly. GLP-1 receptor agonists transformed obesity care in the late 2010s, and newer dual- and triple-agonist peptides are pushing weight loss past 20%. This guide ranks the leading peptides by efficacy, evidence, FDA status, and practical considerations for 2026.
Ranking & Efficacy Comparison
| Rank | Peptide | Mechanism | Max Weight Loss | FDA Status | Dosing |
|------|---------|----------|----------------|------------|--------|
| 1 | Tirzepatide | Dual GIP/GLP-1 | Up to 22.5% | Approved (Zepbound) | Weekly |
| 2 | Retatrutide | Triple GIP/GLP-1/glucagon | Up to 24.2% | Investigational | Weekly |
| 3 | Semaglutide | GLP-1 | 14.9-15.8% | Approved (Wegovy) | Weekly/Oral |
| 4 | Survodutide | GLP-1/glucagon | Up to 19% | Investigational | Weekly |
| 5 | Liraglutide | GLP-1 | 6.4-8.0% | Approved (Saxenda, generic) | Daily |
| 6 | AOD-9604 | hGH fragment 177-191 | Modest/limited data | Investigational | Daily |
1. Tirzepatide (Zepbound, Mounjaro)
Dual GIP/GLP-1 receptor agonist. SURMOUNT-1 demonstrated up to 22.5% weight loss at 72 weeks (15 mg dose), with 91% of patients achieving at least 5% loss. FDA-approved for chronic weight management (2023). The dual incretin mechanism explains its superiority over GLP-1-only agents. Dosing titrates from 2.5 mg to 15 mg weekly.
2. Retatrutide (Investigational)
Triple agonist targeting GIP, GLP-1, and glucagon receptors. The glucagon component adds hepatic fat oxidation and thermogenesis. Phase 2 trials reported up to 24.2% weight loss at 48 weeks — the highest reported for any peptide to date. Phase 3 (TRIUMPH) trials are ongoing; not yet FDA-approved. Watch for approval as early as 2026-2027.
3. Semaglutide (Wegovy, Ozempic)
Pure GLP-1 receptor agonist, the clinical benchmark. STEP 1 showed 14.9% loss at 68 weeks; the SELECT cardiovascular trial added a 20% MACE reduction. Available as weekly injection (2.4 mg) and oral tablet. Well-established safety profile and the strongest long-term data of any GLP-1.
4. Survodutide (Investigational)
Dual GLP-1/glucagon receptor agonist. Early phase 2 data showed up to 19% weight loss. The glucagon component enhances energy expenditure. Phase 3 trials ongoing; not FDA-approved. May compete with retatrutide as a next-generation triple/dual option.
5. Liraglutide (Saxenda, Generic)
First-generation daily GLP-1 agonist. Produces 6.4-8.0% weight loss at 3.0 mg daily. Now available as a generic (2024), making it the most affordable option. Requires daily injection. Suitable for patients who tolerate daily dosing and prioritize cost.
6. AOD-9604 (Investigational)
A modified fragment of human growth hormone (hGH 177-191) designed to retain lipolytic (fat-burning) activity without growth-promoting effects. Early clinical work showed modest fat reduction, but high-quality randomized trial data is very limited and efficacy is far below incretin agonists. Not FDA-approved. Should be considered experimental and used only with caution.
How to Choose
Consider five factors when selecting a weight-loss peptide:
1. **FDA approval status** — Approved agents have established safety and efficacy; investigational options carry more uncertainty.
2. **Efficacy** — Newer dual/triple agonists exceed 20%; GLP-1-only agents deliver 15-16%; liraglutide ~6-8%.
3. **Dosing frequency** — Weekly is more convenient; oral (semaglutide) avoids injection.
4. **Cost & access** — Generic liraglutide is cheapest; newer agents remain expensive and may have supply constraints.
5. **Comorbidities** — Semaglutide has proven cardiovascular benefit; tirzepatide's CVOT is pending; data in hepatic disease (MASH) is emerging for several agents.
Safety Notes
All incretin agonists share GI side effects (nausea, vomiting, diarrhea) and boxed warnings for thyroid C-cell tumors. Retatrutide and survodutide may add glucagon-mediated effects (mild heart rate increase). Any peptide for weight loss should be prescribed and monitored by a qualified clinician — unregulated "research" sources carry serious contamination and dosing risks.
Frequently Asked Questions
Which peptide produces the most weight loss?
Retatrutide has shown up to 24.2% in phase 2 trials, but it is not yet approved. Among FDA-approved options, tirzepatide leads at up to 22.5%.
What is the best FDA-approved weight loss peptide?
Tirzepatide (Zepbound) for efficacy (22.5%) or semaglutide (Wegovy) if you need proven cardiovascular benefit and/or oral dosing.
Is AOD-9604 effective for weight loss?
Evidence is limited. AOD-9604 may modestly reduce fat, but it is far less effective than incretin agonists and is not FDA-approved.
Are retatrutide and survodutide available yet?
No. Both are investigational in phase 3 trials as of 2026. They are not FDA-approved and should not be purchased from unregulated sources.
What is the cheapest weight loss peptide?
Generic liraglutide (Saxenda), available since 2024, is the most affordable option, though it requires daily injection and produces less weight loss.
Referencias
- Jastreboff AM, et al. SURMOUNT-1: Tirzepatide for Obesity. N Engl J Med 2022;387:205-216.
- Wilding JPH, et al. STEP 1: Semaglutide in Adults with Obesity. N Engl J Med 2021;384:989-1002.
- Jastreboff AM, et al. Retatrutide Phase 2 (Obesity, GLP-1/GIP/glucagon). N Engl J Med 2023;389:514-526.
- FDA Prescribing Information: Wegovy, Zepbound, Saxenda.